Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
NCT02920190 on ClinicalTrials.gov · last registry update 2020-09-21
Withdrawn before anyone was enrolled. Its estimated completion date, 1 September 2021, has passed with no update to the record. Primary outcome, as filed: Change in Epicardial Fat Thickness. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- WITHDRAWN
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University of Miami
- Sponsor type
- Other
- Enrollment
- 0
- Started
- 2020-09-01
- Primary completion
- 2021-09-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Epicardial Fat Thickness
Conditions studied
Monoclonal Gammopathies · Overweight · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.